ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: promising trial updates and potential revenue growth from ZYNLONTA are offset by declining revenues and net losses. The Q&A reveals uncertainties in timelines and market adoption challenges. The cost-cutting measures and extended cash runway provide some financial stability, but the lack of specific guidance and potential regulatory hurdles temper optimism. Overall, the sentiment is neutral, as positive developments are balanced by financial and operational concerns.
Key Financial Performance
Net product revenues $15.8 million in Q3 2025, compared to $18 million in Q3 2024, reflecting a decrease due to variability in customer ordering patterns.
Total operating expenses $45 million on a non-GAAP basis in Q3 2025, representing a 12.1% decrease year-over-year, primarily driven by lower R&D expenses while sales and marketing expenses remained stable.
Net loss $41 million in Q3 2025 ($0.30 per share), compared to $44 million in Q3 2024 ($0.42 per share), with the decrease attributed to lower R&D and G&A expenses.
Cash and cash equivalents $234.7 million as of Q3 2025, compared to $250.9 million as of December 31, 2024. Pro forma cash after a $60 million PIPE financing in October 2025 increased to approximately $292.3 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZYNLONTA trials: Progressing in second-line plus DLBCL with updates expected on LOTIS-7 Phase Ib trial and LOTIS-5 Phase III confirmatory trial. Encouraging data in relapsed/refractory follicular lymphoma and marginal zone lymphoma trials.
PSMA-targeting ADC: IND-enabling activities on track to be completed by year-end.
Market expansion for ZYNLONTA: Potential to expand into earlier lines of therapy for DLBCL and indolent lymphomas, with peak annual revenue estimates of $600M-$1B in the U.S.
Combination therapies: LOTIS-5 and LOTIS-7 trials aim to double the addressable patient population and increase therapy duration.
Financial performance: Net product revenues of $15.8M in Q3 2025, with stable quarterly run rate over 2 years. Operating expenses reduced by 12.1% year-over-year.
Cash position: Secured $60M private placement, extending cash runway to 2028.
Strategic focus: Investing in ZYNLONTA to expand into earlier therapy lines and indolent lymphomas. Advancing PSMA-targeting ADC and maintaining financial discipline.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Variability: Net product revenues for ZYNLONTA were $15.8 million in Q3 2025, reflecting variability in customer ordering patterns. This could indicate challenges in achieving consistent revenue growth.
Clinical Trial Risks: The success of ZYNLONTA's expansion into earlier lines of therapy and indolent lymphomas is heavily dependent on the outcomes of ongoing trials like LOTIS-5 and LOTIS-7. Delays or negative results could impact strategic objectives and revenue projections.
Competitive Pressures: The DLBCL treatment landscape is evolving with the introduction of bispecifics and other therapies. ZYNLONTA faces competition from both complex therapies (e.g., CAR T, bispecifics) and broadly accessible therapies (e.g., monoclonal antibodies, chemotherapy).
Regulatory and Approval Risks: The company's ability to expand ZYNLONTA's indications and achieve peak revenue projections depends on regulatory approvals and compendia listings, which are uncertain and time-sensitive.
Financial Sustainability: Despite a strengthened balance sheet with a $60 million private placement, the company reported a net loss of $41 million in Q3 2025. Continued losses could strain financial resources over time.
Market Adoption Challenges: The adoption of ZYNLONTA in new treatment settings depends on demonstrating superior efficacy and safety profiles compared to existing and emerging therapies. Failure to achieve this could limit market penetration.
Supply Chain and Operational Risks: No explicit mention of supply chain issues, but operational risks could arise from the need to scale production and distribution if ZYNLONTA gains broader approval.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ZYNLONTA Revenue Projections: The company projects ZYNLONTA's peak annual revenues in the U.S. to reach $600 million to $1 billion by expanding into earlier lines of therapy for DLBCL and into indolent lymphomas. LOTIS-5 is expected to lift peak annual revenue to $200 million to $300 million in the second-line setting, while LOTIS-7 could expand the total opportunity to $500 million to $800 million in peak annual revenue.
Clinical Trial Updates and Timelines: Top-line results from the LOTIS-5 Phase III trial are expected in the first half of 2026, with potential confirmatory approvals in second-line plus DLBCL by the first half of 2027. A clinical update on LOTIS-7 is anticipated before the end of 2025, with regulatory engagement and potential compendia inclusion by the first half of 2027. Indolent lymphoma trials are progressing, with additional data expected at medical conferences.
Market Expansion Strategy: The company aims to double the addressable patient population for ZYNLONTA by moving into the second-line setting and increasing the duration of therapy from 3 cycles to 5-6 cycles. ZYNLONTA combinations, such as with rituximab and glofitamab, are expected to address unmet needs in both broadly accessible and complex therapy segments.
Financial Position and Cash Runway: With a strengthened balance sheet, including a $60 million private placement, the company expects its cash runway to extend at least to 2028, enabling continued investment in ZYNLONTA and other pipeline programs.
Pipeline Development: The company is advancing IND-enabling activities for its PSMA-targeting ADC, with completion anticipated by the end of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you frame how many patients might be enrolled later this quarter for LOTIS-7, and are you adjusting the target enrollment of 100 patients?
A:Enrollment has accelerated post the June data release, but the target remains at roughly 100 patients. Completion is still expected in the first half of next year, with no exact timeline provided.
Q:Are you still targeting 40 or 40-plus patients for the upcoming LOTIS-7 data release?
A:The data will include more than the original 20 patients per dose group but not all 100. Updates will focus on efficacy-evaluable patients with a minimum of 6 months follow-up for more stable and meaningful data.
Q:When should we expect an inflection point for ZYNLONTA sales, and what is the pace of revenue ramp-up post-approval?
A:LOTIS-7 interim data is expected later this year, with full data by the end of next year or early 2027. LOTIS-5 top-line results are expected in the first half of 2026, with approval in the first half of 2027. Revenue ramp-up is expected to occur mostly within the first two years post-approval.
Q:Would you consider pursuing ZYNLONTA for frontline DLBCL?
A:Frontline DLBCL is a high bar due to existing therapies like Polivy R-CHP. Future development will depend on the readout of the 100 patients and potential partnerships, as the company is unlikely to fund a Phase III study alone.
Q:How will you balance the focus of your sales force between academic and community settings for LOTIS-5 and LOTIS-7?
A:LOTIS-7 will be used in academic centers and sophisticated community centers capable of administering complex therapies. LOTIS-5 will be more broadly accessible, including in community settings, due to its suitability for patients with co-morbidities or limited access to immune-based therapies.
Q:How does each percentage increase in penetration in the second or third-line setting impact ZYNLONTA revenues?
A:In the second-line setting (12,000 patients) and third-line plus setting (6,000 patients), each share point can be calculated based on patient numbers, cycles of therapy (5-6 cycles for LOTIS-5 and LOTIS-7), and net pricing (lower $20,000s per vial). For example, maintaining a 10% share in the second-line setting could increase revenues from $70 million to over $200 million.
Q:Does ZYNLONTA plus rituximab for relapsed/refractory FL have the potential to take market share from bispecifics or T cell therapeutics?
A:The data shows an 84% CR rate, which is competitive with bispecifics and slightly better. However, follicular lymphoma is a highly competitive space with over 10 agents in Phase III trials. The unmet need and competition are lower in marginal zone lymphoma, where ZYNLONTA shows a 70% CR rate.
Q:Review of Unclear Management Responses
A:Management avoided providing exact timelines for LOTIS-7 enrollment completion and revenue ramp-up post-2027. They also did not commit to pursuing frontline DLBCL without partnerships and provided no specific guidance on the pace of revenue ramp-up beyond general industry trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
DLBCL lymphoma
EHA ICML
Hodgkin Lymphoma
II IIT
IND activity
Ib trial
International Workshop
LOTIS Phase
Non Hodgkin
PSMA ADC
Phase II
Phase III
Phase Ib
RD
Workshop Non
approval compendia
balance sheet
bispecifics
center
combination potential
compendia inclusion
cycle
duration therapy
efficacy patient
financing
lead investigator
line setting
lymphoma International
lymphoma patient
monotherapy
month PFS
number event
population
publication compendia
rituximab lymphoma
segment therapy
treatment landscape
treatment segment
trial combination
zone lymphoma
ADCT Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
Unknown5-4
The earnings call shows mixed signals: moderate revenue growth and reduced losses are positive, but increased COGS and lack of clarity in trial timelines are concerning. The Q&A session reveals management's vagueness on crucial data points, which may dampen investor confidence. Although strategic plans are promising, short-term financial health is uncertain. With no significant catalysts or partnerships announced, the stock is likely to remain stable in the short term.
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call summary shows strong financial performance with increased revenues and reduced losses. The company's market expansion strategy for ZYNLONTA and a strengthened cash position are promising. The Q&A section highlights confidence in LOTIS-5 timelines and market projections, with potential upside. Despite some strategic execution risks and management's vague responses on certain aspects, the overall sentiment is positive, especially with the anticipated LOTIS-5 readout. The absence of negative guidance and steady financial health supports a positive outlook for the stock price over the next two weeks.
ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents mixed signals: promising trial updates and potential revenue growth from ZYNLONTA are offset by declining revenues and net losses. The Q&A reveals uncertainties in timelines and market adoption challenges. The cost-cutting measures and extended cash runway provide some financial stability, but the lack of specific guidance and potential regulatory hurdles temper optimism. Overall, the sentiment is neutral, as positive developments are balanced by financial and operational concerns.
ADCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
